Common Contracts
5 similar Employment Agreement contracts by Axcan Intermediate Holdings Inc., Aptalis Pharma Inc
CONFIDENTIAL EMPLOYMENT AGREEMENTEmployment Agreement • December 20th, 2011 • Aptalis Pharma Inc • Pharmaceutical preparations • New York
This AGREEMENT, dated as of February 27, 2011 (the “Agreement”), between Axcan Pharma Inc. (“Axcan”), Axcan Pharma US Inc. (“Axcan US”), Axcan Holdings Inc. (“Parent,” and together with Axcan and Axcan US, the “Company”), and John Fraher (the “Executive”).
AMENDMENT AND RESTATEMENT OF EMPLOYMENT AGREEMENTEmployment Agreement • October 7th, 2008 • Axcan Intermediate Holdings Inc. • Wholesale-drugs, proprietaries & druggists' sundries • New York
This AGREEMENT, dated as May 16th , 2008 (the “Agreement”), between Axcan Pharma, Inc. (“Axcan”), Axcan Pharma US Inc. (“Axcan US”), Axcan Holdings Inc. (“Parent,” and together with Axcan and Axcan US, the “Company”), and Dr. Frank A.G.M. Verwiel (the “Executive”).
EMPLOYMENT AGREEMENTEmployment Agreement • October 7th, 2008 • Axcan Intermediate Holdings Inc. • Wholesale-drugs, proprietaries & druggists' sundries • New York
This AGREEMENT, dated as of June 3, 2008 (the “Agreement”), between Axcan Pharma Inc. (“Axcan”), Axcan Pharma US Inc. (“Axcan US”), Axcan Holdings Inc. (“Parent,” and together with Axcan and Axcan US, the “Company”), and David W. Mims (the “Executive”).
EMPLOYMENT AGREEMENTEmployment Agreement • October 7th, 2008 • Axcan Intermediate Holdings Inc. • Wholesale-drugs, proprietaries & druggists' sundries • New York
This AGREEMENT, dated as of September 15, 2008 (the “Agreement”), between Axcan Pharma Inc. (“Axcan”), Axcan Pharma US, Inc. (“Axcan US”), Axcan Holdings Inc. (“Parent,” and together with Axcan and Axcan US, the “Company”), and Alexandre P. LeBeaut (the “Executive”).
EMPLOYMENT AGREEMENTEmployment Agreement • October 7th, 2008 • Axcan Intermediate Holdings Inc. • Wholesale-drugs, proprietaries & druggists' sundries • New York
This AGREEMENT, dated as of July 3rd, 2008 (the “Agreement”), between Axcan Pharma Inc. (“Axcan”), Axcan Pharma US Inc. (“Axcan US”), Axcan Holdings Inc. (“Parent,” and together with Axcan and Axcan US, the “Company”), and Steven R. Gannon (the “Executive”).
